Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.
J Natl Cancer Inst. 2018 Nov 1;110(11):1248-1258. doi: 10.1093/jnci/djy052.
It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact.
We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014. Standardized incidence ratios (SIRs) quantified second cancer risk. We assessed impact of second cancer development on risk of all-cause mortality using Cox regression.
Among 151 949 one-or-more-year survivors of first primary LN, second primary CM risk was statistically significantly elevated after chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR = 1.96, 95% confidence interval [CI] = 1.74 to 2.21), follicular lymphoma (SIR = 1.32, 95% CI = 1.09 to 1.58), and plasma cell neoplasms (SIR = 1.33, 95% CI = 1.07 to 1.63). Risks for these same subtypes were statistically significantly elevated among 148 336 survivors of first primary CM (SIR = 1.44, 95% CI = 1.25 to 1.66; SIR = 1.47, 95% CI = 1.21 to 1.77; SIR = 1.25, 95% CI = 1.06 to 1.47; respectively). Risk for CM was statistically significantly elevated after diffuse large B-cell lymphoma (SIR = 1.22, 95% CI = 1.02 to 1.45) and Hodgkin lymphoma (SIR = 1.75, 95% CI = 1.33 to 2.26), but the reciprocal relationship was not observed. There were no statistically significant associations between marginal zone lymphoma and CM. Among survivors of most LN subtypes, CM statistically significantly increased risk of death (hazard ratio [HR] range = 1.52, 95% CI = 1.25 to 1.85, to 2.46, 95% CI = 1.45 to 4.16). Among survivors of CM, LN statistically significantly increased risk of death (HR range = 1.75, 95% CI = 1.15 to 2.65, to 6.28, 95% CI = 5.00 to 7.88), with the highest risks observed for the most aggressive LN subtypes.
Heterogeneous associations between CM and specific LN subtypes provide novel insights into the etiology of these malignancies, with the mutual association between CM and certain LN suggesting shared etiology. Development of second primary CM or LN substantially reduces overall survival.
皮肤黑色素瘤 (CM) 和淋巴肿瘤 (LNs) 之间已确定的关联在不同的 LN 亚型中是否存在差异尚不清楚。本研究量化了特定 LN 后发生 CM 的风险,以及相反,CM 后发生特定 LN 的风险,以及评估其临床影响。
我们确定了一个由 17 个美国基于人群的癌症登记处报告的,2000-2014 年间最初诊断为 CM 或 LN 的白种成年人队列(年龄 20-83 岁)。标准化发病率比 (SIR) 量化了第二癌症风险。我们使用 Cox 回归评估第二癌症发展对全因死亡率的影响。
在 151949 名 LN 首次发病一年以上的幸存者中,慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(SIR=1.96,95%置信区间 [CI] = 1.74-2.21)、滤泡性淋巴瘤(SIR=1.32,95%CI = 1.09-1.58)和浆细胞瘤(SIR=1.33,95%CI = 1.07-1.63)后,第二原发 CM 的风险显著升高。在 148336 名 CM 首次发病一年以上的幸存者中,这些相同亚型的风险也显著升高(SIR=1.44,95%CI = 1.25-1.66;SIR=1.47,95%CI = 1.21-1.77;SIR=1.25,95%CI = 1.06-1.47;分别)。弥漫性大 B 细胞淋巴瘤(SIR=1.22,95%CI = 1.02-1.45)和霍奇金淋巴瘤(SIR=1.75,95%CI = 1.33-2.26)后 CM 的风险也显著升高,但没有观察到相反的关系。边缘区淋巴瘤与 CM 之间没有统计学显著关联。在大多数 LN 亚型的幸存者中,CM 显著增加了死亡风险(风险比 [HR] 范围=1.52,95%CI = 1.25-1.85,至 2.46,95%CI = 1.45-4.16)。在 CM 幸存者中,LN 显著增加了死亡风险(HR 范围=1.75,95%CI = 1.15-2.65,至 6.28,95%CI = 5.00-7.88),最具侵袭性的 LN 亚型观察到的风险最高。
CM 和特定 LN 亚型之间的异质关联为这些恶性肿瘤的病因提供了新的见解,CM 和某些 LN 之间的相互关联表明存在共同的病因。第二原发 CM 或 LN 的发生显著降低了总体生存率。